COVID-19 mRNA Vaccines and Regional Lymphadenopathy in BC Patients
COVID-19 has had devastating effects on the world population. Vaccination has had a significant effect on reducing mortality and mortality from SAR-CoV2. Over 1 billion doses have been administered in the United States and Europe. With the widespread administration of the COVID-19 vaccines, reports have surfaced of the development of regional lymphadenopathy in breast cancer (BC) patients. Read more.

Platinum-Based Regimen Offers Survival Benefit in Early-Stage TNBC
Triple negative breast cancer (TNBC) is a highly aggressive form of BC, accounting for 15% to 20% of cases. Platinum agents (i.e., carboplatin and cisplatin) have a significant role in the management of metastatic TNBC (mTNBC), demonstrating improved time to progression or progression-free survival. They may also have a small benefit in overall survival in mTNBC. Read more.

Does Acupuncture Have a Role in Managing Chemotherapy-Induced Leukopenia?
Chemotherapy-induced leukopenia is common following the administration of myelosuppressive agents such as taxanes or cyclophosphamide, which are used in breast cancer (BC) treatment regimens. The occurrence of leukopenia may necessitate the interruption of therapy. Preliminary evidence shows that acupuncture may offer benefit to BC patients by producing an increase in white blood cells and neutrophil counts. Read more.